Modifibio discovers and develops novel therapeutics for cardiometabolic and respiratory diseases using a proprietary macrocyclic peptide platform that delivers high affinity and selectivity for difficult protein targets. The company runs an integrated end‑to‑end drug development pipeline—from target identification and preclinical validation to IND filing and Phase I‑III clinical trials—while collaborating with academic and industry partners to expand its research capabilities.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
5OBFFounders
Product
Problem
Cardiometabolic and respiratory diseases remain leading causes of morbidity and mortality, yet many patients lack effective therapies that target the underlying molecular mechanisms of these conditions.
Solution
Modifibio focuses on discovering and developing novel therapeutics for heart and lung diseases, leveraging advanced macrocyclic peptide technology to create highly specific, biologically active molecules. The company integrates early‑stage discovery, preclinical validation, and clinical development within a single pipeline to accelerate the translation of scientific insights into candidate drugs. By partnering with academic institutions and industry collaborators, Modifibio expands its research capabilities and accesses diverse disease models. Its clinical trial program evaluates safety and efficacy across a range of cardiometabolic and respiratory indications, aiming to deliver new treatment options for patients with unmet medical needs.
Target Audience
Primary customers are pharmaceutical partners, biotech companies, and academic research groups seeking innovative therapeutic candidates for cardiometabolic and respiratory diseases.
Features
- Proprietary macrocyclic peptide platform that enables high affinity and selectivity for challenging protein targets
- Integrated end‑to‑end drug development workflow from target identification through IND filing
- Robust preclinical models for cardiometabolic and pulmonary disease pathways
- Collaborative research framework with academic and industry partners to broaden discovery efforts
- Structured clinical trial infrastructure covering Phase I‑III studies for cardiovascular and respiratory indications